EpiCept Corporation
EpiCept Corporation an emerging leader in pain management
About EpiCept Corporation
Epicept.com specializes in providing comprehensive dissertation writing services tailored to meet the needs of students and researchers. Operating primarily in the academic support market, the company serves clients ranging from undergraduate students to doctoral candidates. The business model revolves around offering customized writing assistance, including topic approval, detailed action plans, and supported conclusions, ensuring that each dissertation is meticulously crafted to meet academic standards. Epicept.com generates revenue through service fees charged for writing, editing, and consulting services. The company leverages a team of experienced writers and researchers to deliver high-quality, plagiarism-free content, ensuring client satisfaction and academic success.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2012 | $0 | — | Immune Pharmaceuticals | — |
| SEED✓Equity / VC | Aug 2007 | — | — | Thuja Capital | — |
Growth signals
Latest recorded traffic for EpiCept Corporation is 200 monthly website visits. EpiCept Corporation's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EpiCept Corporation in the Englewood Cliffs ecosystem
The EpiCept Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Thuja Capital
Series B and later4 investors entered at this stage
Carlyle AlpInvest
TVM Capital Life Science
Excalibur Fund Managers
Kredietrust Luxembourg
Other known investors2 additional known investors
Immune Pharmaceuticals
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EpiCept Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EpiCept Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









